Status:
COMPLETED
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Lead Sponsor:
Janssen Scientific Affairs, LLC
Collaborating Sponsors:
Duke Clinical Research Institute
Bayer
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18-99 years
Brief Summary
The ORBIT-AF registry will be a multicenter, prospective outpatient disease registry to identify "real world" treatment patterns of atrial fibrillation. The registry will describe this patient populat...
Detailed Description
The ORBIT-AF registry is a multicenter prospective outpatient disease registry of patients with incident (initial diagnosis) or prevalent (existing diagnosis) atrial fibrillation (AF) that will analyz...
Eligibility Criteria
Inclusion
- Adult patients with incident (initial diagnosis) or prevalent (existing diagnosis) AF with electrocardiographic documentation
- anticipated ability to adhere to local regularly scheduled follow-up visits
Exclusion
- Anticipated life expectancy less than 6 months
- short lasting AF secondary to a reversible condition (e.g. hyperthyroidism, pulmonary embolism, post-cardiothoracic surgery)
- Participation in a randomized trial of anticoagulation for AF at the time of enrollment
Key Trial Info
Start Date :
June 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
10179 Patients enrolled
Trial Details
Trial ID
NCT01165710
Start Date
June 1 2010
End Date
December 1 2014
Last Update
January 24 2017
Active Locations (171)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States
2
Dothan, Alabama, United States
3
Huntsville, Alabama, United States
4
Mobile, Alabama, United States